Turn Therapeutics Expands Phase 2 After GX-03 Shows 61.5% Clear Skin Rate
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics reported Q2 2026 results and expanded its Phase 2 trial of GX-03 in atopic dermatitis after interim data showed strong efficacy across a broader patient population. The company will enroll 120-135 patients, up from the original plan, targeting patients with moderate-to-severe lesions but lower EASI scores—an underserved group. Interim data showed 61.5% of GX-03 patients achieved clear or almost clear skin at Week 4 versus 8.3% for vehicle, with 46.2% achieving complete clearance at Week 8. The study has 99.8% statistical power and a clean safety profile with no serious adverse events. This follows the July 7 announcement of the final Stage 2 design and the May appointment of former FDA Commissioner Dr. Stephen Hahn. Enrollment completion is expected by end of 2026, with top-line data likely in 2027.
Updates
· SEC 8-K — The 8-K includes the full press release with financial statements: Q2 net loss was $5.85 million, or $0.20 per share, and cash was $10.3 million as of June 30, 2026.
At the time of this announcement, TTRX was trading at $10.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $314M. The 52-week trading range was $2.57 to $26.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.